[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71, 209−49. doi:  10.3322/caac.21660
[2] Zheng RS, Qu CF, Zhang SW, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin J Cancer Res, 2018; 30, 571−9. doi:  10.21147/j.issn.1000-9604.2018.06.01
[3] Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev, 2011; 20, 2362−8. doi:  10.1158/1055-9965.EPI-11-0643
[4] Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. J Natl Cancer Inst, 2021; 113, 1648−69. doi:  10.1093/jnci/djab131
[5] Lewis S, Barry A, Hawkins MA. Hypofractionation in hepatocellular carcinoma - the effect of fractionation size. Clin Oncol (R Coll Radiol), 2022; 34, e195−209. doi:  10.1016/j.clon.2022.02.021
[6] D'Avola D, Granito A, de la Torre-Aláez M, et al. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol, 2022; 76, 1185−98. doi:  10.1016/j.jhep.2021.11.013
[7] Bioulac-Sage P, Gouw ASH, Balabaud C, et al. Hepatocellular adenoma: what we know, what we do not know, and why it matters. Histopathology, 2022; 80, 878−97. doi:  10.1111/his.14605
[8] Vito P, Lacaná E, D'Adamio L. Interfering with apoptosis: Ca2+-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science, 1996; 271, 521−5. doi:  10.1126/science.271.5248.521
[9] la Cour JM, Mollerup J, Winding P, et al. Up-regulation of ALG-2 in hepatomas and lung cancer tissue. Am J Pathol, 2003; 163, 81−9. doi:  10.1016/S0002-9440(10)63632-2
[10] Su D, Xu HY, Feng JG, et al. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. J Transl Med, 2012; 10, 31. doi:  10.1186/1479-5876-10-31
[11] He YQ, Zhou B, Shi SQ, et al. Genetic variation in PDCD6 and susceptibility to lung cancer. Asian Pac J Cancer Prev, 2012; 13, 4689−93. doi:  10.7314/APJCP.2012.13.9.4689
[12] Yamada Y, Arao T, Gotoda T, et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci, 2008; 99, 2193−9. doi:  10.1111/j.1349-7006.2008.00935.x
[13] Zhu GM, Xia HW, Tang QL, et al. An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients. Cancer Cell Int, 2021; 21, 166. doi:  10.1186/s12935-021-01864-5
[14] Thiery JP, Acloque H, Huang RYJ, et al. Epithelial-mesenchymal transitions in development and disease. Cell, 2009; 139, 871−90. doi:  10.1016/j.cell.2009.11.007
[15] Yan Z, Kui Z, Ping Z. Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis. Autoimmun Rev, 2014; 13, 1020−5. doi:  10.1016/j.autrev.2014.08.028
[16] Bellacosa A, Testa JR, Staal SP, et al. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science, 1991; 254, 274−7.
[17] Mroweh M, Roth G, Decaens T, et al. Targeting Akt in hepatocellular carcinoma and its tumor microenvironment. Int J Mol Sci, 2021; 22, 1794. doi:  10.3390/ijms22041794
[18] Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol, 2008; 48, 83−90. doi:  10.1016/j.jhep.2007.08.018
[19] Li Q, Sun MQ, Wang ML, et al. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application. Cancer Sci, 2021; 112, 1695−706. doi:  10.1111/cas.14861
[20] Xu CR, Xu Z, Zhang Y, et al. β-Catenin signaling in hepatocellular carcinoma. J Clin Invest, 2022; 132, e154515. doi:  10.1172/JCI154515
[21] Wen SY, Chen YY, Deng CM, et al. Nerigoside suppresses colorectal cancer cell growth and metastatic potential through inhibition of ERK/GSK3β/β-catenin signaling pathway. Phytomedicine, 2019; 57, 352−63. doi:  10.1016/j.phymed.2018.12.033
[22] Zhang DK, Wang F, Pang Y, et al. ALG2 regulates glioblastoma cell proliferation, migration and tumorigenicity. Biochem Biophys Res Commun, 2017; 486, 300−6. doi:  10.1016/j.bbrc.2017.03.032
[23] Yoon JH, Choi YJ, Kim SG, et al. Programmed cell death 6 (PDCD6) as a prognostic marker for gastric cancers. Tumour Biol, 2012; 33, 485−94. doi:  10.1007/s13277-011-0280-4
[24] Aviel-Ronen S, Coe BP, Lau SK, et al. Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci U S A, 2008; 105, 10155−60. doi:  10.1073/pnas.0709618105
[25] Ambatipudi S, Gerstung M, Gowda R, et al. Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome. PLoS One, 2011; 6, e17250. doi:  10.1371/journal.pone.0017250
[26] Rho SB, Song YJ, Lim MC, et al. Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell Signal, 2012; 24, 131−9. doi:  10.1016/j.cellsig.2011.08.013
[27] Suzuki K, Dashzeveg N, Lu ZG, et al. Programmed cell death 6, a novel p53-responsive gene, targets to the nucleus in the apoptotic response to DNA damage. Cancer Sci, 2012; 103, 1788−94. doi:  10.1111/j.1349-7006.2012.02362.x
[28] De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer, 2013; 13, 97−110. doi:  10.1038/nrc3447
[29] Mani SA, Guo WJ, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 2008; 133, 704−15. doi:  10.1016/j.cell.2008.03.027
[30] Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev, 2009; 28, 151−66. doi:  10.1007/s10555-008-9179-y
[31] Sánchez-Danés A, Blanpain C. Deciphering the cells of origin of squamous cell carcinomas. Nat Rev Cancer, 2018; 18, 549−61. doi:  10.1038/s41568-018-0024-5
[32] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol, 2014; 15, 178−96. doi:  10.1038/nrm3758
[33] Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene, 2008; 27, 6958−69. doi:  10.1038/onc.2008.346
[34] Taciak B, Pruszynska I, Kiraga L, et al. Wnt signaling pathway in development and cancer. J Physiol Pharmacol, 2018; 69, 185−96.
[35] Fattahi S, Amjadi-Moheb F, Tabaripour R, et al. PI3K/AKT/mTOR signaling in gastric cancer: epigenetics and beyond. Life Sci, 2020; 262, 118513. doi:  10.1016/j.lfs.2020.118513
[36] Aoki T, Nishida N, Kudo M. Clinical significance of the duality of Wnt/β-catenin signaling in human hepatocellular carcinoma. Cancers (Basel), 2022; 14, 444. doi:  10.3390/cancers14020444
[37] Valenta T, Hausmann G, Basler K. The many faces and functions of β-catenin. EMBO J, 2012; 31, 2714−36. doi:  10.1038/emboj.2012.150
[38] Bretones G, Delgado MD, León J. Myc and cell cycle control. Biochim Biophys Acta, 2015; 1849, 506−16. doi:  10.1016/j.bbagrm.2014.03.013
[39] Moldogazieva NT, Zavadskiy SP, Sologova SS, et al. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Rev Mol Diagn, 2021; 21, 1147−64. doi:  10.1080/14737159.2021.1987217